← All trials
NCT05094206
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2022
- Primary completion
- Feb 28, 2025
- Completion date
- Feb 28, 2026
- First posted
- Oct 26, 2021
- Last posted
- Nov 1, 2021
- Enrollment
- 24
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medical College of WisconsinLead sponsor
- Medical College of WisconsinReponsible party - principal investigator
- Medical College of WisconsinOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.